Loading stock data…
Dyadic International, Inc. (DYAI)
$0.52-0.00 (-0.02%)
Market ClosedLast close Sep 8
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Dyadic International, Inc. in the Healthcare sector is trading at $0.52 with a market capitalization of $21M. Wall Street consensus targets $5.50 (2 analysts), implying a +957.5% move over the next 12 months. The stock is currently near its 52-week low of $0.48, remaining 39.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 9 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +957.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 9) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $123,886↓ | $623,590↑ | $235,716↓ | $350,046↓ | $463,449 |
| Gross Profit | -$860,279↓ | -$168,250↓ | -$148,892↑ | -$673,957↓ | -$150,142 |
| Operating Income | -$2.05M↓ | -$1.91M↓ | -$1.52M↑ | -$1.91M↓ | -$1.71M |
| Net Income | -$2.12M↓ | -$1.95M↓ | -$1.57M↑ | -$1.98M↓ | -$1.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$20.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.96
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
319.27%
Volume
Today's trading volume
153,144
Recent News
Dyadic International (DYAI) Q2 2026 Earnings Call Transcript
Company advances commercialization with initial product shipments and distribution deals.
Dyadic International, Inc. Q2 2026 Earnings Call Summary
Moby summary of Dyadic International, Inc.'s Q2 2026 earnings call
Dyadic International Inc (DYAI) (Q2 2026) Earnings Call Highlights: Revenue Surges 52% as ...
Despite a 52% revenue increase and significant productivity gains, Dyadic International Inc (DYAI) faces a going concern uncertainty, requiring additional capital within the next 12 months.
Dyadic (DYAI) Q1 2026 Earnings Call Transcript
Joseph Hazelton: Thanks, Ping, and thank you, everyone, for joining us today. As we recently held our full year 2025 earnings call, today, we want to build on the updates we provided in March by focusing on the continued operational and commercial progress we're making across the business and why we believe Dyadic is increasingly well positioned for the future. Over the last several years, we have worked to transform Dyadic from a platform technology company into a commercially focused biotechnology company capable of generating recurring revenues from products, partnerships, licensing opportunities and strategic collaborations.
Dyadic International, Inc. Q1 2026 Earnings Call Summary
Moby summary of Dyadic International, Inc.'s Q1 2026 earnings call